In agreement with this hypothesis, atherosclerosis associated biomarkers showed good prognostic capacity to predict CVE in CKD patients [4], and the combination of some biomarkers associated with the presence of atheromatous plaque like Osteoprotegerin (OPG), Osteopontin (OPN) and soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) increased the accuracy of predictive models for cardiovascular outcomes in CKD patients [5]. This evidence concerns the gene SPP1 and chronic kidney disease.